Global Information
회사소개 | 문의 | 비교리스트

고지혈증 치료제 시장(2019-2025년)

Hyperlipidemia Drug Market 2019-2025

리서치사 Orion Market Research Pvt Ltd
발행일 2020년 06월 상품 코드 949570
페이지 정보 영문
가격
US $ 3,600 ₩ 4,243,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,658,000 Printable PDF (Enterprise License)


고지혈증 치료제 시장(2019-2025년) Hyperlipidemia Drug Market 2019-2025
발행일 : 2020년 06월 페이지 정보 : 영문

세계의 고지혈증 치료제 시장은 예측기간 중 낮은 CAGR로 성장할 것으로 추정됩니다. 콜레스테롤 환자수 증가는 세계의 고지혈증 치료제 시장을 추진하고 있습니다. WHO에 의하면 고콜레스테롤혈증으로 매년 260만명 이상이 사망한다고 추정됩니다. 미국 성인의 약 37.0%가 높은 LDL-C 레벨입니다. 그럼에도 불구하고 50.0% 미만의 환자가 어떠한 치료를 받고 있으며, 치료를 받고 있는 환자의 약 33.0%가 정상적인 지질 레벨에 달성하지 못하고 있습니다. 그러나 고지혈증 치료제의 부작용이 시장 성장을 억제하고 있습니다.

세계의 고지혈증 치료제 시장에 대해 조사했으며, 시장 개요와 함께 약제 클래스별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.

목차

제1장 보고서 개요

제2장 시장 개요와 인사이트

  • 조사 범위
  • 애널리스트의 인사이트와 현재 시장 동향

제3장 경쟁 상황

  • 기업 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석
    • AstraZeneca PLC
    • Novartis AG
    • Mylan N.V.
    • Pfizer, Inc.
    • Sanofi-Aventis S.A.

제4장 시장 결정요인

  • 성장 촉진요인
  • 성장 억제요인
  • 시장 기회

제5장 시장 세분화

  • 약물 클래스별 세계의 고지혈증 치료제 시장
    • HMG-CoA 환원효소 억제제(Statins)
    • PCSK9 억제제
    • 콜레스테롤 흡수 억제제
    • 피브린산 유도체(Fibrates)
    • Niacin(니코틴산)
    • 담즙산 봉쇄제(BAS)
    • 병용요법
    • 기타

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타
  • 기타 지역

제7장 기업 개요

  • Abbott Laboratories
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co., Ltd.
  • Dr.Reddy's Laboratories, Ltd.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi-Aventis S.A.
  • Sun Pharmaceutical Industries, Ltd.
  • Teva Pharmaceutical Industries, Ltd.
KSM 20.08.18

LIST OF TABLES

  • 1. GLOBAL HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 2. GLOBALHMG-COA REDUCTASE INHIBITORS (STATINS)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 3. GLOBAL PCSK9 INHIBITORSMARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 4. GLOBAL CHOLESTEROL ABSORPTION INHIBITORSMARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 5. GLOBAL FABRIC ACID DERIVATIVES (FIBRATES)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 6. GLOBAL NIACIN (NICOTINIC ACID)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 7. GLOBAL BILE ACID SEQUESTRANTS(BAS)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 8. GLOBAL COMBINATION THERAPYMARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 9. GLOBAL OTHERSHYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 10. GLOBAL HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 11. GLOBAL HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 12. NORTH AMERICAN HYPERLIPIDEMIADRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 13. NORTH AMERICAN HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 14. EUROPEAN HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 15. EUROPEAN HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BYDRUG CLASS, 2018-2025 ($ MILLION)
  • 16. ASIA-PACIFIC HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 17. ASIA-PACIFIC HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY DRUGCLASS, 2018-2025 ($ MILLION)
  • 18. REST OF THE WORLD HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY DRUGCLASS, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL HYPERLIPIDEMIA DRUG MARKET SHARE BYDRUG CLASS, 2018 VS 2025 (%)
  • 2. GLOBAL HYPERLIPIDEMIA DRUG MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 3. US HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 4. CANADA HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. UK HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. FRANCE HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. GERMANY HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. ITALY HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. SPAIN HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. ROE HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. INDIA HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. CHINA HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. JAPAN HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF THE WORLD HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)

Global Hyperlipidemia Drug Market Size, Share & Trends Analysis Report, By Drug Class (HMG-CoA Reductase Inhibitors (Statins), PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Fabric Acid Derivatives (Fibrates), Niacin (Nicotinic Acid), Bile Acid Sequestrants(BAS), Combination Therapy, and Others) and Forecast Period 2019-2025

The global hyperlipidemiadrug market is estimated to grow at a low CAGR during the forecast period.The increasing number of cholesterol patients is propelling the global hyperlipidemiadrug market. As per WHO, hypercholesterolemia is estimated to result in more than 2.6 million deaths each year. Almost 37.0% of adults in the US have high LDL-C levels. Yet, lesser than 50.0% of patients receive any form of treatment and approximately 33.0% of patients undergoing treatment are unable to achieve normal lipid levels.However, the side effects of hyperlipidemia drugs are restraining the growth of the market.

The global hyperlipidemia drug market is segmented based on the drug class. Based on the drug class the market is segmented into HMG-CoA reductase inhibitors (statins), PCSK9 inhibitors, cholesterol absorption inhibitors, fabric acid derivatives (fibrates), niacin (nicotinic acid), bile acid sequestrants(BAS), combination therapy and others.Geographically, theglobal hyperlipidemiadrug market is segmented based on the region including North America, Europe, Asia-Pacific, and the Rest of the world (RoW).

The major manufactures of the hyperlipidemiadrug includeAmgen Inc.,Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., Ionis Pharmaceuticals, Inc., Mylan N.V, GlaxoSmithKline PLC Pfizer, Inc.,Sanofi-Aventis S.A.,Merck & Co., Inc.,Dr.Reddy's Laboratories, Ltd. and others.These companies are continuously making efforts to provide innovative products in the market.For instance, in April 2019, TtheUS FDA also approved Sanofi's Praluent. It is used as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce LDL-C.

Research Methodology

The market study of the global hyperlipidemiadrug market is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Reports of companies involved in the market
  • Authentic Public Databases
  • Whitepapers such as research papers and news blogs
  • Company websites and their product catalog

The report is intended for providers, suppliers, and distributors of hyperlipidemia drugs, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and will serve as a source for 360-degree analysis of the market.

Market Segmentation-

  • Global HyperlipidemiaDrugs Market Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global hyperlipidemiadrug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Insights about market determinants which are stimulating the global hyperlipidemiadrug market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusions

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AstraZeneca PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Novartis AG
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Mylan N.V.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Pfizer, Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Sanofi-Aventis S.A.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Hyperlipidemia Drug Marketby Drug Class
    • 5.1.1. HMG-CoA Reductase Inhibitors (Statins)
    • 5.1.2. PCSK9 Inhibitors
    • 5.1.3. Cholesterol Absorption Inhibitors
    • 5.1.4. Fabric Acid Derivatives (Fibrates)
    • 5.1.5. Niacin (Nicotinic Acid)
    • 5.1.6. Bile Acid Sequestrants(BAS)
    • 5.1.7. Combination Therapy
    • 5.1.8. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Amgen, Inc.
  • 7.3. AstraZeneca PLC
  • 7.4. Bristol-Myers Squibb Co.
  • 7.5. Daiichi Sankyo Co., Ltd.
  • 7.6. Dr.Reddy's Laboratories, Ltd.
  • 7.7. GlaxoSmithKline PLC
  • 7.8. Ionis Pharmaceuticals, Inc.
  • 7.9. Merck & Co., Inc.
  • 7.10. Mylan N.V.
  • 7.11. Novartis AG
  • 7.12. Pfizer, Inc.
  • 7.13. Sanofi-Aventis S.A.
  • 7.14. Sun Pharmaceutical Industries, Ltd.
  • 7.15. Teva Pharmaceutical Industries, Ltd.
Back to Top
전화 문의
F A Q